[
  {
    "ts": null,
    "headline": "Kura Oncology: Sentiment Is Too Negative",
    "summary": "Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive acquisition target despite its promising AML drug candidate ziftomenib.",
    "url": "https://finnhub.io/api/news?id=46441af9688d4fa33268aee576f15c513d161762142ba0239f85a6ecea546cba",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737644120,
      "headline": "Kura Oncology: Sentiment Is Too Negative",
      "id": 132450161,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184964962/image_184964962.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive acquisition target despite its promising AML drug candidate ziftomenib.",
      "url": "https://finnhub.io/api/news?id=46441af9688d4fa33268aee576f15c513d161762142ba0239f85a6ecea546cba"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth, Caterpillar share gains contribute to Dow's 250-point jump",
    "summary": "UnitedHealth, Caterpillar share gains contribute to Dow's 250-point jump",
    "url": "https://finnhub.io/api/news?id=f36eb0c33cad82c82570ef34c504209467aa988759750916a643ad2d0181d933",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737631380,
      "headline": "UnitedHealth, Caterpillar share gains contribute to Dow's 250-point jump",
      "id": 132458946,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "UnitedHealth, Caterpillar share gains contribute to Dow's 250-point jump",
      "url": "https://finnhub.io/api/news?id=f36eb0c33cad82c82570ef34c504209467aa988759750916a643ad2d0181d933"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan Chase, Goldman Sachs share gains lead Dow's 125-point jump",
    "summary": "JPMorgan Chase, Goldman Sachs share gains lead Dow's 125-point jump",
    "url": "https://finnhub.io/api/news?id=e1b62d74109900299afcb2f06238cbe1352e74b98831ada284edd91f36e9f142",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737625560,
      "headline": "JPMorgan Chase, Goldman Sachs share gains lead Dow's 125-point jump",
      "id": 132458783,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "JPMorgan Chase, Goldman Sachs share gains lead Dow's 125-point jump",
      "url": "https://finnhub.io/api/news?id=e1b62d74109900299afcb2f06238cbe1352e74b98831ada284edd91f36e9f142"
    }
  },
  {
    "ts": null,
    "headline": "J&J: positive results in generalized myasthenia gravis",
    "summary": "Johnson & Johnson reports that The Lancet Neurology has published the results of a Phase 3 study of nipocalimab, evaluated in a large population of antibody-positive adults with generalized...",
    "url": "https://finnhub.io/api/news?id=34d236957b59984f0f38bc16ea16c6e4ddc0bb7bcfcfea812d2076e4de517f75",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737625394,
      "headline": "J&J: positive results in generalized myasthenia gravis",
      "id": 132448837,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson reports that The Lancet Neurology has published the results of a Phase 3 study of nipocalimab, evaluated in a large population of antibody-positive adults with generalized...",
      "url": "https://finnhub.io/api/news?id=34d236957b59984f0f38bc16ea16c6e4ddc0bb7bcfcfea812d2076e4de517f75"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson exceeds expectations for fourth quarter",
    "summary": "Copyright © BusinessAMBE 2023Key takeawaysJohnson & Johnson reported $22.5 billion in revenue and adjusted earnings per share of $2.04.Darzalex sales increased 20 percent to $3.08...",
    "url": "https://finnhub.io/api/news?id=205b4b99f58f2a390c8c5e6ef72a8d418fa3b87e7a59bbad2911107285f4a87d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737622903,
      "headline": "Johnson & Johnson exceeds expectations for fourth quarter",
      "id": 132448578,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Copyright © BusinessAMBE 2023Key takeawaysJohnson & Johnson reported $22.5 billion in revenue and adjusted earnings per share of $2.04.Darzalex sales increased 20 percent to $3.08...",
      "url": "https://finnhub.io/api/news?id=205b4b99f58f2a390c8c5e6ef72a8d418fa3b87e7a59bbad2911107285f4a87d"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour",
    "summary": "Underscores the urgent need for improved diagnosis and clinical management of psoriasis in patients with skin of colour and enhanced treatment standards ...",
    "url": "https://finnhub.io/api/news?id=776510bb03024fe3231e70683f621ab7cc3b16e70d17ae55fb6bc1c6dcb2bcb2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737619291,
      "headline": "Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for patients with skin of colour",
      "id": 132448209,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Underscores the urgent need for improved diagnosis and clinical management of psoriasis in patients with skin of colour and enhanced treatment standards ...",
      "url": "https://finnhub.io/api/news?id=776510bb03024fe3231e70683f621ab7cc3b16e70d17ae55fb6bc1c6dcb2bcb2"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson reports Q4 2024 and Full-Year 2024 results",
    "summary": "New Brunswick - Johnson & Johnson today announced results for fourth-quarter and full year 2024.'2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating...",
    "url": "https://finnhub.io/api/news?id=4fb4c8b16f686646b3d5a97607fb969d2fce359ca16f5f387c7e7cdd41c86f2b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737611356,
      "headline": "Johnson & Johnson reports Q4 2024 and Full-Year 2024 results",
      "id": 132447472,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "New Brunswick - Johnson & Johnson today announced results for fourth-quarter and full year 2024.'2024 was a transformative year for Johnson & Johnson, marked by strong growth, an accelerating...",
      "url": "https://finnhub.io/api/news?id=4fb4c8b16f686646b3d5a97607fb969d2fce359ca16f5f387c7e7cdd41c86f2b"
    }
  },
  {
    "ts": null,
    "headline": "Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology",
    "summary": "The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+Nipocalimab demonstrated a sustained reduction in...",
    "url": "https://finnhub.io/api/news?id=cd5cc3f7931be509f5e601a80c3d114437da8267f5d12de23ceaae32977b6701",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737610565,
      "headline": "Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology",
      "id": 132447377,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "The first FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adult patients: anti-AChR+, anti-MuSK+, anti-LRP4+Nipocalimab demonstrated a sustained reduction in...",
      "url": "https://finnhub.io/api/news?id=cd5cc3f7931be509f5e601a80c3d114437da8267f5d12de23ceaae32977b6701"
    }
  }
]